New stock news: Ankin Bioscience plans to list on the Hong Kong Stock Exchange. The China Securities Regulatory Commission requires additional information on whether the company continues to meet the requirements of foreign investment access policies before and after this issuance and listing.

On September 5th, the China Securities Regulatory Commission announced the "Supplementary Materials Requirement for Overseas Issuance and Listing (August 29, 2025 - September 4, 2025)", and the International Department of the CSRC issued supplementary material requirements to 12 companies. Among them, Ama Bio was required to provide additional explanations on whether they continued to meet the requirements of the foreign investment access policy before and after this issuance and listing. According to the disclosure by the Hong Kong Stock Exchange on June 17th, Ama BioTechnology Co., Ltd. submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC SEC and CICC as joint sponsors. The CSRC asked Ama Bio to provide explanations on the following matters and requested lawyers to verify and provide clear legal opinions: 1. Please provide a conclusive opinion on whether the significant changes in equity ownership of the main domestic operating entities have been legal and compliant in the past, summarize the situation of the issuer and domestic shareholders in performing foreign exchange registration, overseas investment, foreign investment procedures in the process of building the company's equity structure, and provide a conclusive opinion on whether it complies with the regulatory rules at that time on foreign exchange management, overseas investment, foreign investment, tax management, etc. 2. Please explain the establishment and equity changes of the largest shareholder, Sanaron Inc., and clarify the relationship between the actual controller and the beneficiaries of the trust after the above-mentioned shareholder is penetrated. 3. Everlasting Wisdom Holdings Limited holds a 5.37% equity stake in the issuer, please explain the natural person shareholder information after penetrating upwards according to the "Regulatory Rules Applicable Guidelines - Overseas Issuance and Listing No. 2", and provide reasons for the shareholding of the two shareholders, Yajun Xu and their backgrounds, the fairness of the pricing at the time of entry, and whether there are any relationships with the directors, senior executives, or business operations of the issuer. 4. Please explain the business scope and actual operations of the issuer and its subsidiaries in connection with the drug R&D technology route, whether they are involved in "human stem cells, gene diagnostics and treatment technology development and application," or other areas with foreign investment access restrictions or prohibitions, and the basis for related judgments, and whether they continue to meet the requirements of the foreign investment access policy before and after this issuance and listing. According to the prospectus, Ama Bio is a clinical-stage biotechnology company at the forefront of innovation in the field of bispecific antibody therapy, focusing on developing T-cell connectors to treat various cancers and autoimmune diseases globally. Ama Bio's oncology pipeline includes three clinical-stage candidate drugs, including (i) the core product EMB-01 (targeting EGFR/cMET) for treating colorectal cancer, (ii) two key products based on T-cell connectors EMB-06 (targeting BCMA/CD3) for treating multiple myeloma ("MM") and EMB-07 (targeting ROR1/CD3) for treating lymphoma and solid tumors, and (iii) three preclinical candidate drugs based on T-cell connectors EM1032 (targeting ALPP(G)/CD3), EM1034 (targeting LY6G6D/CD3), and EM1031 (targeting KLK2/CD3). Ama Bio's immunology pipeline includes a clinical-stage candidate drug, the key product EMB-06 based on T-cell connectors, and two preclinical candidate drugs EM1039 and EM1042 based on T-cell connectors.